Simoctocog Alfa Safe, Effective for Managing Inhibitors in Hemophilia A
Researchers evaluated whether simoctocog alfa, a fourth-generation recombinant factor VIII product, is safe and effective in patients with severe hemophilia A.
Diagnosis & Disease Information
Inhibitors Do Not Cause Early Mortality in Nonsevere Hemophilia A
Median age at inhibitor development was 13 years, and the inhibitor-related mortality rate was 2.44 per 1000 person-years.
Long-Term Follow-Up of BCMA-Directed CAR-T in R/R MM: CRs Appear Durable in LEGEND-2
Long-term follow-up from the clinical trial investigating LCAR-B38M, a BCMA-targeting CAR-T, revealed that approximately three-quarters of patients achieved a complete response.
Promising Results Expected for Canakinumab in Sickle Cell Anemia
A multicenter, randomized, parallel group, double-blind, placebo-controlled trial found that canakinumab may be well tolerated by pediatric patients with sickle cell anemia.
Complement Activation in Thrombotic and Catastrophic Antiphospholipid Syndrome
Patients with catastrophic antiphospholipid syndrome were more likely to have positive modified Ham assays and rare germline mutations compared with other cohorts.
The Role of Erythroferrone in Regulating Iron Metabolism, Erythropoiesis in Beta Thalassemia
Mice with thalassemia with ERFE loss exhibited increased osteoblast and osteoclast activity and decreased bone formation.
Evidence of Benefit of Mosunetuzumab in Relapsed/Refractory NHL Following CAR-T Cell Therapy
Mosunetuzumab may offer a survival benefit, particularly in patients who have relapsed after the receipt of CAR-T.
Posttransplantation Cyclophosphamide-Based Regimen Found More Effective Than Conventional Immunosuppression in Lowering Risk of GVHD
Patients were randomly assigned to receive either cyclophosphamide followed by cyclosporine A or cyclosporine A plus mucophenolic acid following allogeneic HSCT.
Adding Eltrombopag to Immunosuppression Did Not Change Outcomes in Pediatric Severe Aplastic Anemia
Researchers found that the addition of eltrombopag to standard immunosuppression therapy did not provide therapeutic benefit to pediatric patients with SAA.
Comparison of Reduced-Intensity Conditioning Regimens for Transplant in Myelodysplastic Syndromes
Though fludarabine and melphalan led to increased treatment-related mortality, the combination also led to decreased relapse incidence compared with fludarabine and busulfan.
- Loading...
Loading...
Next post in ASH 2019
Loading... 
Loading...